Právní předpis byl sestaven k datu 02.03.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx věcí,
kterým xx xxxx x xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;
Xxxxxxxxxxxx zahraničních xxxx sděluje, že xxx 1. xxxxx 2023 bylo generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx I - Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx sportu.
S xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx změn Přílohy X Xxxxxx xxxxxxxxxx.
Xxxx xxxxx Xxxxxxx I xxxxxxxxx x xxxxxxxx x xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx vstoupilo x xxxxxxxx xxx 18. června 2024 x xxxxxxxxx Xxxxxxx X xxx rok 2023, xxxxxxx xx 1. ledna 2023, xxxxx xxxxxxxxx v xxxxxxxx pro Českou xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx vyhlášena xxx č. 32/2023 Sb. m. s.
Xxxxxxxx xxxxx Přílohy X xxx rok 2024 x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;
Xxxxxxx:
x x. XXXx. Xxxxxx, Xx.X., XX.X., x. x.
xxxxxx ředitel xxxxx právní x xxxxxxxxxx
&xxxx;
Xxxxxxx x. 1
Xxxxxxx xxxxxxxxxxx xxxxxxx xx xxxxxxx xxxxxx
Xxxx
Xxxxxx zakázaných xxxxx a metod xxxxxxx xx xxxxxxx Xxxxxxxxxxx standard x xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx xx každoročně xxxxxxxxxxxx po xxxxxxxxx xxxxxxxxxxxx procesu zprostředkovaném Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Seznam je xxxxxx xx 1. xxxxx 2024.
Xxxxxxxxx text Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxx xxxxxxxxx WADA x xxxx publikován x xxxxxxxxxx x francouzštině. X xxxxxxx jakýchkoliv xxxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx textem xxxxxxxxx znění x xxxxxxxxxx.
Xxxx xxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxx x tomto Xxxxxxx xxxxxxxxxx látek x xxxxx.
Xxxxxxxx Xxx xxxxxxx
Xxxxx XXXX xxx daný xxxxx xxxxxxxxxxx jiné xxxxxx, je xxxxxx Xxx xxxxxxx x xxxxxx xxxxxxx začínajícím xxxxx xxxx půlnocí (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx se xx Xxxxxxxxx zúčastnit, xx xx xxxxx Xxxxxxx x procesu xxxxxx Xxxxxx.
Xxxxxxxx stále
To xxxxxxx, že xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Mimo xxxxxx, xxx xx xxxxxxxxxx v Xxxxxx.
Xxxxxxxxxx x Xxxxxxxxxxxx
Xxxxx článku 4.2.2 Světového xxxxxxxxxxxxxxx Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx všechny Zakázané xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx těch xxxxxxxxxx x Xxxxxxx xxxxxxxxxx xxxxx a xxxxx dopingu. Xxxxx Xxxxxxxx xxxxxx nebude Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Xxxxxxx xxxxxxxxx xxxxxxxx jako Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx xxxxxxx x xxxxxx 4.2.2 xx neměly xxx xxxxxx xxxxxxxx považovány xx xxxx xxxxxxxx xxxx xxxx xxxxxxxxxx xxx xxxx xxxxxxxxx xxxxx xxxx xxxxxx. Xxx spíše x xxxxx x xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx nebo použil x xxxxxx xxxxx xxx xx zlepšení xxxxxxxxxxx xxxxxx.“
Xxxxxxxx xxxxx
Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx látky, xxxxx xxxx xxxx xxxxxx xxxxxxxx x xxxxxx xxxxxx častého xxxxxxxxxx ve společnosti xxxx xxxxx sportu. Xxxx Xxxxxxxx látky xxxx xxxxxxxxxx xxxx xxxxx: kokain, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).
X0 XXXXXXXXXXX XXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, na xxxxxx xx nevztahuje xxxxx x následujících xxxxxx Xxxxxxx x xxxxx xxxx x xxxxxxxx xxxx xxxxxxxxx xxxxxx vládním xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx u xxxx (xxxx. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx zakázána stále.
Tato xxxxx zahrnuje mnoho xxxxxxx látek, xxxx xxxx BPC-157, 2,4-dinitrofenol (XXX) x xxxxxxxxxx xxxxxxxxx (xxxx. Xxxxxxxxxxx x Xxxxxxxxxx).
X1 XXXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX I MIMO XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Nespecifické látky.
Anabolické xxxxx xxxx xxxxxxxx.
X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)
Xxx exogenním xxxxxx, xxxx jiné xxxxxx:
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol) |
• |
formebolon |
|
|
• |
1-androstenedion (5ɑ-xxxxxxx-1-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx) |
|
|
• |
1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on) |
• |
mesterolon |
|
|
• |
4-androstenediol (androst-4-en-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx) |
|
|
• |
4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
7ɑ-xxxxxxx-XXXX |
&xxxx;• |
xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on) |
|
|
• |
7-keto-DHEA |
• |
metylklostebol |
|
|
• |
11ß-metyl-19-nortestosteron |
• |
metyldienolon (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx) |
|
|
• |
19-xxxxxxxxxxxxxxxxx (estr-4-en-3,17-diol) |
• |
metyltestosteron |
|
|
• |
19-norandrostenedion (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-hydroxy-5ɑ-androstan-3-on) |
• |
nandrolon (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol) |
• |
norboleton |
|
|
• |
androstenedion (androst-4-en-3,17-dion) |
• |
norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxx |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on) |
• |
prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx) |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxx-xxxxxxxxxxxxxxxxxx (17β-hydroxy-5β-androstan-3-on) |
• |
tetrahydrogestrinon (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx) |
&xxxx;• |
xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX) |
x další xxxxx x xxxxxxxx xxxxxxxxx strukturou nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X1.2. XXXXXXX XXXXXXXXXX LÁTKY
Mimo xxxx včetně:
Clenbuterol, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx receptorů [XXXX, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], zeranol x xxxxxxxxxx.
X2 PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, PŘÍBUZNÉ XXXXX X XXXXXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx látky.
Následující látky x xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx jsou xxxxxxxx.
X2.1. ERYTROPOETINY (XXX) X XXXXX XXXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx xxxxxx:
X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx receptorů, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (EPO); xxxxxxxxxx xxxxxxxx xx XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, xxxxxxxxxxx.
X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), xxxx. xxxxxx; daprodustat (XXX1278863); XXX2; xxxxxxxxxx (BAY 85-3934); roxadustat (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.
X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.
X2.1.4 Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx faktoru xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5 Agonisté xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. asialo XXX; xxxxxxxxxxxxx XXX (XXXX).
X2.2. XXXXXXXXX HORMONY X XXXXXX XXXXXXXXXX XXXXXXX
X2.2.1 Xxxxxxx stimulující xxxxxxxxxxx x xxxx, xxxx xxxx včetně:
• xxxxxxxx xxxxxxxxxxxx (XX),
• luteinizační xxxxxx (LH),
• hormon xxxxxxxxxx xxxxxxxxxxxx (GnRH, xxxxxxxxxxx) x jeho xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, goserelin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x triptorelin),
• xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.
X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.
X2.2.3 Xxxxxxx xxxxxx (XX), jeho xxxxxxx x xxxxxxxxx, xxxx xxxx xxxxxx:
• analogy xxxxxxxxx xxxxxxx, např. xxxxxxxxxxxxxxxxx, somapacitan a xxxxxxxxxx,
• xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x hGH 176–191.
X2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, xxxx jiné xxxxxx:
• hormon uvolňující xxxxxxx xxxxxx (XXXX) x jeho xxxxxxx, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx x xxxxxxxxxxx,
• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) x jejich xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, xxxxxxxxxxx (ghrelin), xxxxxxxxxxx x xxxxxxxxxxx],
• xxxxxxx xxxxxxxxxx GH (XXXX) [xxxx. alexamorelin, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), GHRP-3, XXXX-4, XXXX-5 a XXXX-6].
X2.3. XXXXXXX XXXXXXX X MODULÁTORY RŮSTOVÝCH XXXXXXX
Xxxx xxxx včetně:
• xxxxxxxxxxxxx růstové xxxxxxx (XXX)
• hepatocytový růstový xxxxxx (HGF)
• růstový xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x xxxx xxxxxxx
• xxxxxxxxxx růstové faktory (XXX)
• růstový xxxxxx xxxxxxxx z krevních xxxxxxxx (XXXX)
• xxxxxxxx-β4 x jeho xxxxxxxx, xxxx. TB-500
• vaskulárně-endoteliární xxxxxxx xxxxxx (VEGF)
a xxxxx růstové faktory xxxx xxxxxxxxxx růstových xxxxxxx ovlivňující syntézu/degradaci xxxxxxxx xx xxxxxxx, xxxxxxxx nebo xxxxxx, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.
X3 XXXX-2 AGONISTÉ
ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxx v xxxx třídě xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx selektivní x neselektivní xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx jsou xxxxxxxx.
Xxxx jiné včetně:
|
• |
arformoterol |
• |
indakaterol |
• |
reproterol |
• |
tretoquinol (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 mikrogramů xx 24 xxxxx x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 hodin xx jakékoliv dávce;
• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx za 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx xx 24 xxxxx.
XXXXXXXX
Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxx vyšším xxx 1000 ng/ml xxxx xxxxxxxxxxx v xxxxxxxx xxxxxx než 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xxxxx x xxxx xxxxxxxxxx xx Xxxxxxxxx laboratorní xxxxx (XXX), pokud Sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (inhalační) xx do výše xxxxxxx xxxxxxxxx dávky.
S4 XXXXXXXXX A METABOLICKÉ XXXXXXXXXX
XXXXXXXX STÁLE (PŘI XXXXXXX X MIMO XXXXXX)
Xxxxxxxx látky ve xxxxxxx X4.1 a X4.2 xxxx Specifické xxxxx.
Xxxxx xxxxxxxx xx xxxx X4.3 x X4.4 jsou Nespecifické xxxxx.
Xxxxxxxxxxx hormonové x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
X4.1. XXXXXXXXXX XXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on) |
• |
androsta-3,5-dien-7,17-dion (xxxxxxxxx) |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on) |
• |
formestan |
|
|
• |
4-androsten-3,6,17 trion (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. ANTIESTROGENNÍ XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX RECEPTORŮ (XXXXX)]
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX AKTIVINU XXX
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx xxxxxxxxxxxxxx aktivin X |
• |
xxxxxxxxxx xxxxxxxxxx, např.: |
|
|
• |
konkurenty xxxxxxxxx xxxxxxxx XXX, xxxx.: |
- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx xxxxxxxxxx |
||
|
- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031) |
- xxxxxxxx xxxxxx xxxxxxxxx (např. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx) |
|||
|
• |
xxxxxxxxxx xxxxx xxxxxxxxx aktivinu XXX (např. xxxxxxxxxx) |
- xxxxxxxxxx neutralizující xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, stamulumab) |
S4.4. METABOLICKÉ XXXXXXXXXX
X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (AMPK), např. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx receptoru xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) kyselina xxxxxx (XX1516, GW501516) x xxxxxxxx Xxx-xxxɑ , xxxx. XX9009, XX9011
X4.4.2 xxxxxxxx x xxxxxxxx insulinů
S4.4.3 meldonium
S4.4.4 xxxxxxxxxxxx
X5 XXXXXXXXX A XXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX SOUTĚŽI I XXXX XXXXXX)
Xxxxxxx zakázané xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- a x-, xxxx xxxxxxxx.
Xxxx xxxx včetně:
• Xxxxxxxxx, xxxx např.:
acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx a hydrochlorothiazid; xxxxxxxxx; xxxxxxxxxx;
• Vaptany, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;
• Plazmatické xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:
xxxxxxx, xxxxxxx, hydroxyetyl xxxxx, xxxxxxxx;
• Desmopresin;
• Xxxxxxxxxx;
x xxxxx látky s xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
XXXXXXX
• drospirenon; xxxxxxxx; x lokální xxxxxxxxxxxxxx xxxxxxxx inhibitorů karboanhydrázy (xxxx. dorzolamid, xxxxxxxxxxx);
• xxxxxxx podání xxxxxxxxxxx x xxxxx xxxxxxxxx.
XXXXXXXX
Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx stanoveným prahovým xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxx případně Xxx Soutěži ve xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx nebo xxxxxxxxx xxxxxx felypresinu x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx nebo jinou xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxxx x xxxx třídě xxxx Xxxxxxxxxxxx s xxxxxxxx xxxxx x X2.2, xxx jsou Specifické xxxxxx.
X1. MANIPULACE X XXXX A XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X1.1. Xxxxxx nebo xxxxxxxx xxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx krve xxxx produktů x xxxxxxxxx krvinek xxxxxxxxxxx xxxxxx xx oběhového xxxxxxx x xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy provedené x registrovaném odběrovém xxxxxx.
X1.2. Umělé zvyšování xxxxxx, přenosu xxxx xxxxxxx xxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x modifikované xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xx xxxx hemoglobinu a xxxxxxxxxxxxxxxx hemoglobinové produkty, x xxxxxxxx xxxxxxxxxxx xxxxxxx inhalací.
M1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx nebo xxxxxxxxxx xxxxxxx.
X2. CHEMICKÁ A XXXXXXXXX MANIPULACE
Zakázané xx xxxxxxxxxxx:
X2.1. Xxxxxxxxx nebo Xxxxx x podvod xx účelem porušit xxxxxxxxx x platnost Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.
Xxxx jiné xxxxxx:
Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. přidáním xxxxxxx ke Vzorku.
M2.2. Xxxxxxxxxx infuze a/nebo xxxxxxx více než xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx ošetření, chirurgických xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx vyšetření.
M3. XXXXXX X XXXXXXX XXXXXX
X xxxxxx potencionálního zvýšení xxxxxxxxxxx výkonu xx xxxxxxxx následující:
M3.1. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx analogů, které xxxxx xxxxxx xxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx mimo xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx xxxxxxx xxxx.
X3.2. Xxxxxxx normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.
X6 XXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx x xxxxxxxx látek xxxxxxxxx x X6.X, xxx jsou Xxxxxxxxxxxx xxxxx.
Xxxxxxxx látky x xxxx xxxxx: kokain x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)
Všechna xxxxxxxxxxx, včetně xxxxx xxxxxxxxx izomerů, xxxx. x- x l-, xxxx zakázána.
Stimulancia zahrnují:
S6.A: XXXXXXXXXXXX STIMULANCIA
|
• |
adrafinil |
• |
fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, xxxxx není xxxxxxxx xxxxxx x xxxxx oddíle, xx Xxxxxxxxxxx xxxxxx.
X6.X: SPECIFICKÁ XXXXXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, metylhexanamin) |
• |
heptaminol |
• |
pentetrazol |
||
|
• |
4-methylpentan-2-amin (1,3-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxx (xxxxxxxxx) |
• |
xxxxxxxxxxx x xxxx xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (parahydroxyamfetamin) |
• |
fenmetrazin |
||
|
• |
benzfetamin |
• |
isomethepten |
• |
fenprometamin |
||
|
• |
katin1) |
• |
levmetamfetamin |
• |
propylhexedrin |
||
|
• |
katinon x xxxx xxxxxxx, např. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxx3) |
• |
xxxxxxxxxxxx3) |
• |
xxxxxxxxxx |
||
|
• |
xxxxxxxxx (adrenalin)4) |
• |
metylnaftidát [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát] |
• |
solriamfetol |
||
|
• |
etamivan |
• |
metylfenidát |
• |
strychnin |
||
|
• |
etylfenidát |
• |
niketamid |
• |
tenamfetamin (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x další látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx
XXXXXXX
• klonidin;
• xxxxxxxx xxxxxxxxxxx x xxxxxxx jejich kožního, xxxxxxx, xxxxxx xxxx xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxymetazolin, xxxxxxxxxx, xxxxxxxxxx, xylometazolin) x stimulancia zařazená xx Xxxxxxxxxxxxxx programu 20245).
X7 NARKOTIKA
ZAKÁZANÉ PŘI XXXXXXX
Xxxxxxx zakázané xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x této xxxxx: xxxxxxxxx (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx optických xxxxxxx, xxxx. x- x x, xxxx xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx x xxxx xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (xxxxxx) |
• |
xxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxxx |
X8 XXXXXXXXXXX
XXXXXXXX XXX SOUTĚŽI
Všechny zakázané xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x této xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)
Xxxxxxx přírodní x xxxxxxxxxx xxxxxxxxxxx xxxx zakázané, xxxx.
• x konopí (xxxxx, xxxxxxxxx) a konopných xxxxxxxxxx
• xxxxxxxx a xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)
• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx XXX
XXXXXXX
• xxxxxxxxxx
X9 XXXXXXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě jsou Xxxxxxxxxx xxxxx.
Xxxxxxx glukokortikoidy xxxx xxxxxxxx, pokud xxxx podávány xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (xxxx. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx xxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Xxxx xxxxxxx xxxxxx (včetně xxxxxxxxxxx a xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx xx xxxxxxxxx x rámci xxxxxxxx xxxxxxxxxxxx xxxxx a xxxxxxxxxxxxxx indikací.
P1 XXXX-XXXXXXXXX
XXXXXXXX X XXXXXXXX SPORTECH
Všechny xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx xxxx xxxxxxxx pouze v xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx x xxx xx xx xxxxxxxx xxxxxxxx (*) x Xxxx soutěž.
• xxxxxxxxxxx (XX)*
• xxxxxxxx/xxxxxxxxxxxx (FIS) – skoky xx xxxxxx, akrobatické xxxxx / X-xxxxx a xxxxxxxxx U-rampa / xxx air
• xxxxxxxxxxxx xxxxx (XXX)
• xxxxxxxx xxxxxx (XXXX)* x xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx x xxxxxxx na xxxx
• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
• xxxxx (XXX)
• xxxx (IGF)
• xxxxxxxx (XXX)
• střelba (XXXX, XXX)*
* zakázané xxxx Xxxx xxxxxx
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx x. 2
Znění xxxxxxxxxxx xxxxxxx v xxxxxxxxx jazyce
1) xxxxx (x-xxxxxxxxxxxxxxxx) a xxxx x-xxxxxx: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx.
2) xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 150 mikrogramů x 1 ml.
3) xxxxxxx x metylefedrin: xxxxxxxx xxx xxxxxxxxxxx v xxxx xxxxx xxx 10 xxxxxxxxxx x 1 ml.
4) xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, např. xxxxx, oční, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx anestetiky.
5) xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, kofein, xxxxxxx, xxxxxxxxx a xxxxxxxx: tyto xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx látky.
Xxxxxxxxx
Xxxxxx předpis x. 19/2025 Sb. nabyl xxxxxxxxx xxxx 28.1.2024.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x odkazech není xxxxxxxxxxxxx, xxxxx xx xxxx netýká derogační xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx